Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).


TSXV:SBM - Post by User

Bullboard Posts
Post by MirrorWorldManon Sep 26, 2019 6:50pm
141 Views
Post# 30168512

Signed Deal evaluation

Signed Deal evaluationI see the Wanbang deal as about a dime on the TSX (which was the SP after the last lightener deal died back early 2019). Our OS was about 180 MM at that time, so the MC valuation was $18 MM. To cut things with a chainsaw after measuring with a lazer, Its not perfect math but $18MM can be subtracted from our current Market Cap and hence the market evaluation of 1067 (with one signed deal and all its scientific data) presently to be around $80 MM or a about $.36 per share. Share price is what it is regardless if its perceived to be undervalued. Its a possible gauge to forecast the China deal if it’s similar in design. So extrapolating further, a new 20 kg worth of inventory to fill new R + F orders is worth about .36 to the share price. If this new manufacturing facility in China makes 40 kg on top of the repeat R + F orders then SP may rise another $.72 and we may see our $1+ per share. I know its all full of holes but at least we have one signed deal of history now. 
Bullboard Posts